Three items on ministerial list of technologies with high level of innovation

The Health Ministry has published a list of technologies with a high level of innovation:

after consultation with the Transparency Council, National Consultants and the Patient Ombudsman, the Minister of Health publishes the current list of highly innovative technologies on the basis of the list of highly innovative drug technologies prepared by the Agency for Health Technology Assessment and Tarification:

1. dabrafenib mesylate - in combination with trametinib for the treatment of children and adolescents aged 1 year and older with high-grade glioma (HGG) with the BRAF V600E mutation who have received at least one prior course of treatment with radiotherapy and/or chemotherapy;
2. dabrafenib mesylate - in combination with trametinib for the treatment of children and adolescents aged 1 year and older with low-grade glioma (LGG) with the BRAF V600E mutation who require systemic therapy;
3. ivosidenib - in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with a mutation in the gene encoding isocitrate dehydrogenase 1 (IDH1) R132 who are not qualified to receive standard induction chemotherapy.

Source: MZ